Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026)
Penumbra (PEN) posted quarterly Total Non-Current Liabilities of $429.7 million for Q2 2026, up 18.36% year-over-year from $363.0 million in Q2 2025, and up 4.46% quarter-over-quarter from $411.4 million in Q1 2026.
Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Total Non-Current Liabilities for 13 consecutive years, with $429.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 18.36% year-over-year to $429.7 million; the TTM figure through Jun 2026 stood at $429.7 million (up 18.36% YoY), while the FY2025 annual figure was $386.6 million, up 5.3% from the prior year.
- Total Non-Current Liabilities advanced to $429.7 million in Q2 2026 per PEN's latest filing, from $411.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $429.7 million in Q2 2026 and bottomed at $338.7 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $370.3 million across 5 years, with a median of $366.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 85.68% — and 2025, when it fell 1.61%.
- Penumbra's Total Non-Current Liabilities stood at $368.8 million in 2022, then grew by 0.9% to $372.1 million in 2023, then dropped by 1.32% to $367.1 million in 2024, then increased by 5.3% to $386.6 million in 2025, then climbed by 11.15% to $429.7 million in 2026.
- Business Quant data shows PEN's Total Non-Current Liabilities at $429.7 million in Q2 2026, $411.4 million in Q1 2026, and $386.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.43 Bn | 193.83 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.99 Bn | 122.51 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.19 Bn | 108.97 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 72.95 Bn | 72.41 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.75 Bn | 47.50 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.45 Bn | 32.50 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.58 Bn | 31.47 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.07 Bn | 22.75 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.07 Bn | 22.58 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | 429.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 429.71 Mn |
| Mar 31, 2026 | 411.38 Mn |
| Dec 31, 2025 | 386.60 Mn |
| Sep 30, 2025 | 371.14 Mn |
| Jun 30, 2025 | 363.04 Mn |
| Mar 31, 2025 | 364.48 Mn |
| Dec 31, 2024 | 367.14 Mn |
| Sep 30, 2024 | 365.39 Mn |
| Jun 30, 2024 | 365.71 Mn |
| Mar 31, 2024 | 370.44 Mn |
| Dec 31, 2023 | 372.05 Mn |
| Sep 30, 2023 | 360.97 Mn |
| Jun 30, 2023 | 362.70 Mn |
| Mar 31, 2023 | 367.59 Mn |
| Dec 31, 2022 | 368.75 Mn |
| Sep 30, 2022 | 344.55 Mn |
| Jun 30, 2022 | 354.41 Mn |
| Mar 31, 2022 | 338.66 Mn |
| Dec 31, 2021 | 286.77 Mn |
| Sep 30, 2021 | 281.00 Mn |